Implanet Announces Definitive Clinical Results in a Comparative Study of the JAZZ Band in Idiopathic Scoliosis Surgery

  • Excellent performance of JAZZ compared with the Zimmer Universal Clamp
  • JAZZ offers improved tensioning capabilities
  • Enhanced corrective power, improved profile, easy-to-learn procedure, reduced operative time and blood loss with a global reduction in the overall cost of surgery

PARIS--()--Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces the publication of a new White Paper entitled “Comparison of two polyester sublaminar bands for the treatment of thoracic adolescent idiopathic scoliosis with CoCr rods: Jazz versus Universal Clamp”, which presents the results of a comparative study of two sublaminar bands in the treatment of idiopathic scoliosis with posteromedial translation.

This study, carried out by the Department of Pediatric Orthopedic Surgery at the Robert Debré hospital, which is part of Paris Diderot University, represents the final phase of the JAZZ Band’s clinical validation and highlights its safety and efficiency in the treatment of idiopathic scoliosis. The study was based on 18-month follow-up of a consecutive series of 115 patients.

These results confirm the efficacy of combining the posteromedial translation technique with rigid chrome-cobalt rods, enabling sagittal alignment to be restored in patients suffering from idiopathic scoliosis”, states Prof. Brice Ilharreborde, MD, Ph.D, adding “The ease of use of the JAZZ implant and the considerable force generated by the tensioning instrument make surgery easier and allow substantial and lasting deformity correction. The small number of implants needed to suitably treat these deformities makes it possible to significantly reduce the overall cost of adolescent idiopathic scoliosis surgery.”

Ludovic Lastennet, CEO of Implanet, says: “The results of this major study confirm that the JAZZ implant offers surgeons an exciting alternative to existing traditional systems, given its excellent radiological outcomes, low complication rate and significantly reduced operative time and intraoperative blood loss. The proven efficacy of our JAZZ implant in adolescent scoliosis surgery is very encouraging, and provides the clinical platform to address other clinical indications, in particular in degenerative spine surgery.

Although many surgeons still advocate using assemblies consisting entirely of screws for this type of patient, the results of this study show that the JAZZ system should be considered, in particular when treating hypokyphotic patients.

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surge Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.
Ticker: IMPL - ISIN code: FR0010458729

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr
or
NewCap
Press Relations
Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr
or
NewCap
Press Relations
Nicolas Merigeau, Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr